Non-opioid Pain Treatment: Global Markets to 2022
The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a compound annual growth rate (CAGR) of 18.0% for the period of 2017-2022.
- 46 data tables and 19 additional tables
- An overview of the global market for non-opioid pain treatments
- Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Market breakdown by type, segment, indication, application, and country
- Identification of segments with high growth potential and their future applications
- Explanation of major drivers and regional dynamics of the market and current trends within the industry
- Detailed profiles of major vendors in the market, including Allergan Plc, Aphria Inc., Canopy Growth Corp., Cara Therapeutics and Cronos Group
This BCC Research report is designed to be a helpful business tool that will provide a thorough evaluation of the markets for pain management. The geographical scope of this study is global. This study addresses acute versus chronic pain, treatments and regulatory issues facing healthcare workers. Also provided is detailed information based on product categories, use of products, forecasts and competitive analyses.
The report identifies five general product segments for non-opioid treatment of pain:
- Medical cannabis treatments.
- Capsaicin-derived treatments.
- Menthol-containing treatments.
- Omega 3 fatty acid-containing treatments.
- Botulinum toxins.
Within the segment several sub-segments are discussed as they pertain to each product segment; diseases or disorders are the basis for these sub-segments, including:
- Cancer-brain, breast, colorectal, leukemia/lymphoma, melanoma, prostate, others.
- Multiple sclerosis.
A regional analysis of these product segments is also provided, including the specific countries listed below and including countries not listed as a “rest of the world” market.
- Australia/New Zealand.
- United Kingdom.
- United States.
Each market segment provides detailed information based on product categories, product use, current market value and forecasts.
Not covered in the report are drugs or devices that are considered “conventional” in professional treatment guidelines that are due to either controversial issues such as those with medical cannabis or those that are not commonly prescribed or recommended due to a lack of clinical data, education or other factors.
MELISSA ELDER is a healthcare market analyst specializing in treatments, medical equipment and devices. As a research analyst for more than 20 years, she also worked in medical training and advanced medical technologies. She holds a B.S. degree in business management and is pursuing an MBA in health care management from California Coast University.